August 2002
Worldwide Biotech;Aug2002, Vol. 14 Issue 8, p1
Trade Publication
Reports on the formation of a drug discovery collaboration between Argenta Discovery Ltd. and Amedis Pharmaceuticals Ltd. in 2002. INSET: About Amedis Pharmaceuticals Ltd.


Related Articles

  • Artificial Intelligence in Drug Discovery: A Case Study. Thomas, Karen; Basman, Antranig; White, Cat; Higgs, Chris; Clark, David // Pharmaceutical Technology Europe;May2003 Supplement, Vol. 15, p27 

    Reports on Argenta Discovery's collaboration with Amedis Pharmaceuticals to add a virtual element to its screening services, with the expansion of its in silico screening capabilities. Benefits of in silico absorption, distribution, metabolism, excretion and toxicity (ADMET) models; Early...

  • Argenta to Collaborate with Armedis Pharmaceuticals.  // Drug Discovery & Development;Jul/Aug2002, Vol. 5 Issue 7, p19 

    Reports on the drug discovery collaboration between Argenta Discovery Ltd. and Amedis Pharmaceuticals Ltd. in Great Britain.

  • ARGENTA/NOVARTIS SIGN TWO-YEAR DRUG DISCOVERY PACT.  // Worldwide Biotech;Mar2005, Vol. 17 Issue 3, p6 

    Announces the drug discovery contract between Argenta Discovery Ltd. and Novartis in March 2005. Terms of the agreement; Remarks from Argenta CEO Chris Ashton on the collaboration; Efforts of the companies to develop diabetes therapies; Background of Argenta Discovery Ltd.

  • OTHER NEWS TO NOTE.  // BioWorld International;10/31/2007, Vol. 12 Issue 44, p5 

    This section offers news briefs concerning biotechnology. The integrated contract drug discovery agreement of Argenta Discovery Ltd. with Genentech Inc. was extended for a further two-year period. A $10 million fund will be received by BTG plc from its licensee Tolerx Inc. A research agreement...

  • Movers. Finch, Harry // Nature;2/17/2005, Vol. 433 Issue 7027, p782 

    Profiles Harry Finch, senior vice-president of therapeutics at Argenta Discovery Ltd. in Great Britain. Career background; Job responsibilities; Industrial affiliations.

  • in brief.  // Pharmaceutical Technology Europe;May2004 Supp, Vol. 16, p7 

    The article presents news related to the pharmaceutical industry. Avecia Inc. has announced a new early phase production unit for DNA medicines (oligonucleotides) at its Grangemouth biotechnology facility. Sandoz AG has opened a new cell culture as manufacturing faculty in Schaftenaueu...

  • Reddy deals.  // Pharmaceutical Technology Europe;Mar2006, Vol. 18 Issue 3, p16 

    The article reports that Dr. Reddy's Laboratories Ltd. and Argenta Discovery Ltd. have created a partnership which will focus on the growing problem of chronic obstructive pulmonary disease. The drug companies will work together to identify clinical compounds from Dr. Reddy's lead compounds. The...

  • OTHER NEWS TO NOTE.  // BioWorld International;3/7/2007, Vol. 12 Issue 10, p3 

    The article offers news briefs on biotechnology. A contract services agreement has been signed by Affectis Pharmaceuticals Inc. with Dalton Pharma Services to produce pre-clinical tox materials. A European Development Center has been opened by Amgen Inc. in London, England to support its...

  • CLINIC ROUNDUP.  // BioWorld Today;5/19/2009, Vol. 20 Issue 95, p7 

    This section offers news briefs on the pharmaceutical industry in 2009. Argenta Discovery has announced the launch of Phase I safety and tolerability studies for a candidate drug from a potential collaboration with AstraZeneca plc. Essentialis Inc. has announced that its primary endpoint of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics